EBI-02

N/A

Report date: 2024/09/04 17:31:01

Base Information

Drug NameEBI-02

Drug Alias NameEBI-02

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsLiver Cirrhosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTherabest INC

China Registration ClassN/A

Develop Information

Active CompaniesTherabest INC

Inactive CompaniesN/A

Active IndicationsLiver Cirrhosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A